Want to join the conversation?
$XL 2Q15 PR: "I’m pleased to announce the first quarterly financial results for the combined XL Catlin. We reported $0.84 of operating EPS and delivered an annualized operating ROE excluding unrealized gains and losses on investments of 10%. We are very excited about where we are and what lies ahead for XL Catlin,” said, Mike, CEO.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.